Welcome to our dedicated page for Eagle Pharmaceut news (Ticker: EGRX), a resource for investors and traders seeking the latest updates and insights on Eagle Pharmaceut stock.
Eagle Pharmaceuticals, Inc. reports developments tied to its specialty pharmaceutical portfolio, research and development programs, and public-company governance. The company combines research and development, clinical, manufacturing, and commercial capabilities, with commercialized products including PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® in Japan, and BYFAVO® through Acacia Pharma Inc. Its pipeline is described around oncology and CNS/metabolic critical care product candidates.
Recurring Eagle news includes portfolio actions such as the U.S. Barhemsys marketing-authorization divestiture, availability of audited and unaudited financial statements, annual meeting materials and voting results, board and stockholder matters, and amendments to its limited-duration stockholder rights plan.
Eagle Pharmaceuticals, Inc. (EGRX) announced the availability of its pre-recorded presentation at the Piper Sandler 32nd Annual Virtual Healthcare Conference. The presentation can be viewed via a link provided in the release and will also be available on Eagle's website for 30 days. Additionally, CEO Scott Tarriff and CFO Brian Cahill will engage in 1x1 meetings on December 1, 2020, which can be requested through Piper Sandler. The company remains focused on developing innovative medicines for critical care and oncology.
Eagle Pharmaceuticals (Nasdaq: EGRX) reported a strong financial performance for Q3 2020, with total revenue reaching $49.9 million, up from $41.1 million in Q3 2019. Net income for the quarter was $7.1 million, or $0.52 per share, compared to a net loss of $2.4 million last year. The company received FDA Priority Review for its vasopressin ANDA, added key executives to its leadership, and approved a $25 million share repurchase plan. Despite COVID-19 delays, Eagle remains optimistic about upcoming product launches and continued growth.
Eagle Pharmaceuticals (Nasdaq: EGRX) has appointed four new executives to strengthen its clinical and commercialization teams: Dr. Judi Ng-Cashin as EVP and Chief Medical Officer, John Kimmet as EVP of Oncology and Acute Care Marketing, Dr. Valentin R. Curt as SVP of Clinical Drug Development, and Dr. Gaozhong Zhu as SVP of Pharmaceutical Development. Brian Cahill has been promoted to Chief Financial Officer. The new leadership is expected to bolster Eagle's efforts in advancing its pipeline products, including EA-114, and support future growth strategies.
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced it will release its 2020 third-quarter financial results on November 2, 2020, prior to market opening. CEO Scott Tarriff and CFO Pete Meyers will host a conference call at 8:30 a.m. ET to discuss the results. Investors can access the call by dialing 866-342-8591 (U.S.) or 203-518-9713 (International). A replay will be available for one week after the call. Eagle is a fully integrated pharmaceutical company focused on developing innovative medicines to improve patients' lives.